623P KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Omlin, AG; Graff, JN; Hoimes, CJ; Tagawa, ST; Hwang, C; Kilari, D; Ten Tije, AJ; McDermott, R; Vaishampayan, UN; Elliott, T; Gerritsen, WR; Wu, H; Kim, J; Schloss, C; de Bono, JS; Antonarakis, ES

Published Date

  • September 2020

Published In

Volume / Issue

  • 31 /

Start / End Page

  • S514 - S515

Published By

International Standard Serial Number (ISSN)

  • 0923-7534

Digital Object Identifier (DOI)

  • 10.1016/j.annonc.2020.08.882